UK Biobank (core renewal)
Lead Research Organisation:
UK Biobank
Department Name: UNLISTED
Abstract
UK Biobank is supported by The Wellcome Trust, The National Institute of Health Research, The Medical Research Council, The British Heart Foundation and Cancer Research UK. The figures presented on this record represent the Medical Research Council funding contribution only with some additional UKRI Infrastructure funds in addition.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
Technical Summary
The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. There are now sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
Organisations
People |
ORCID iD |
Rory Collins (Principal Investigator) |
Publications
Griffanti L
(2022)
Adapting UK Biobank imaging for use in a routine memory clinic setting: The Oxford Brain Health Clinic.
in NeuroImage. Clinical
Johnson J
(2022)
Added Sugars Intake Explained by Amino Acid Carbon Isotope Ratio Profiles in a Controlled Feeding Study of U.S. Adults
in Current Developments in Nutrition
Ma H
(2022)
Adding salt to foods and hazard of premature mortality.
in European heart journal
Larvin H
(2021)
Additive Effect of Periodontal Disease and Obesity on COVID-19 Outcomes.
in Journal of dental research
Georgakis MK
(2022)
Additive Effects of Genetic Interleukin-6 Signaling Downregulation and Low-Density Lipoprotein Cholesterol Lowering on Cardiovascular Disease: A 2×2 Factorial Mendelian Randomization Analysis.
in Journal of the American Heart Association
Tanriver G
(2023)
Additive pre-diagnostic and diagnostic value of routine blood-based biomarkers in the detection of colorectal cancer in the UK Biobank cohort.
in Scientific reports
Geng T
(2022)
Adherence to a Healthy Sleep Pattern and Risk of Chronic Kidney Disease: The UK Biobank Study.
in Mayo Clinic proceedings
Zhou T
(2022)
Adherence to a healthy sleep pattern is associated with lower risks of all-cause, cardiovascular and cancer-specific mortality.
in Journal of internal medicine
Karavasiloglou N
(2022)
Adherence to cancer prevention recommendations and risk of breast cancer in situ in the United Kingdom Biobank.
in International journal of cancer
Polkinghorne M
(2022)
Adipose tissue derived ceramides regulate myocardial redox state and predict cardiovascular outcomes
in European Heart Journal
Guo W
(2018)
Adiposity and breast cancer risk in postmenopausal women: Results from the UK Biobank prospective cohort.
in International journal of cancer
Ahmed M
(2021)
Adiposity and cancer: a Mendelian randomization analysis in the UK biobank.
in International journal of obesity (2005)
Pinto Pereira SM
(2022)
Adiposity and grip strength: a Mendelian randomisation study in UK Biobank.
in BMC medicine
Perez-Cornago A
(2022)
Adiposity and risk of prostate cancer death: a prospective analysis in UK Biobank and meta-analysis of published studies.
in BMC medicine
Shang X
(2021)
Adiposity by Differing Measures and the Risk of Cataract in the UK Biobank: The Importance of Diabetes.
in Investigative ophthalmology & visual science
Pillay P
(2022)
Adiposity, Body Fat Distribution, and Risk of Major Stroke Types Among Adults in the United Kingdom.
in JAMA network open
Kizil C
(2022)
Admixture Mapping of Alzheimer's disease in Caribbean Hispanics identifies a new locus on 22q13.1.
in Molecular psychiatry
Hartmann S
(2022)
ADRA2A and IRX1 are putative risk genes for Raynaud's phenomenon
Lai FY
(2018)
Adult height and risk of 50 diseases: a combined epidemiological and genetic analysis.
in BMC medicine
Ukraintseva S
(2022)
ADULT INFECTIONS ARE ASSOCIATED WITH HIGHER RISK OF ALZHEIMER'S DISEASE BUT LOWER RISK OF CANCER
in Innovation in Aging
Perrotta ML
(2020)
Adults With Mild-to-Moderate Congenital Heart Disease Demonstrate Measurable Neurocognitive Deficits.
in Journal of the American Heart Association
Borga M
(2023)
Advanced Body Composition Assessment: From Body Mass Index to Body Composition Profiling
in Journal of Investigative Medicine
Nabulsi L
(2022)
Advanced diffusion-weighted MRI sensitively detects age and sex effects in 34,423 adults
in Alzheimer's & Dementia
Raisi-Estabragh Z
(2021)
Adverse cardiovascular magnetic resonance phenotypes are associated with greater likelihood of incident coronavirus disease 2019: findings from the UK Biobank.
in Aging clinical and experimental research
Linge J
(2021)
Adverse muscle composition predicts all-cause mortality in the UK Biobank imaging study.
in Journal of cachexia, sarcopenia and muscle
Lawrence KE
(2021)
Age and sex effects on advanced white matter microstructure measures in 15,628 older adults: A UK biobank study.
in Brain imaging and behavior
Li M
(2021)
Age and sex specific effects of APOE genotypes on ischemic heart disease and its risk factors in the UK Biobank.
in Scientific reports
Ni G
(2018)
Age at first birth in women is genetically associated with increased risk of schizophrenia.
in Scientific reports
Gill D
(2018)
Age at menarche and adult body mass index: a Mendelian randomization study.
in International journal of obesity (2005)
Deng P
(2023)
Age at Menarche Mediating Visceral Adipose Tissue's Influence on Pre-eclampsia: A Mendelian Randomization Study.
in The Journal of clinical endocrinology and metabolism
Van Der Plaat DA
(2019)
Age at menopause and lung function: a Mendelian randomisation study.
in The European respiratory journal
Ehakeem A
(2020)
Age at puberty and accelerometer-measured physical activity: Findings from two independent UK cohorts.
in Annals of human biology
Minelli C
(2018)
Age at puberty and risk of asthma: A Mendelian randomisation study.
in PLoS medicine
Ambikairajah A
(2020)
Age, menstruation history, and the brain.
in Menopause (New York, N.Y.)
Raisi-Estabragh Z
(2020)
Age, sex and disease-specific associations between resting heart rate and cardiovascular mortality in the UK BIOBANK.
in PloS one
Chen H
(2023)
Age- and sex-specific modifiable risk factor profiles of dementia: evidence from the UK Biobank.
in European journal of epidemiology
Nazlee N
(2022)
Age-associated sex and asymmetry differentiation in hemispheric and lobar cortical ribbon complexity across adulthood: A UK Biobank imaging study.
in Human brain mapping
Le Goallec A
(2019)
Age-dependent co-dependency structure of biomarkers in the general population of the United States.
in Aging
Bellou E
(2020)
Age-dependent effect of APOE and polygenic component on Alzheimer's disease.
in Neurobiology of aging
Zhang B
(2023)
Age-level bias correction in brain age prediction
in NeuroImage: Clinical
Description | Impact of clinically silent atrial fibrillation on cerebrovascular disease and cognitive decline in the UK Biobank Imaging Cohort |
Amount | £2,474,260 (GBP) |
Funding ID | RG/18/6/33576 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 06/2019 |
End | 06/2024 |
Description | UK Biobank - The Repeat Imaging Project |
Amount | £2,500,000 (GBP) |
Funding ID | R39738/CN039 |
Organisation | MRC Dementias Platform UK |
Sector | Academic/University |
Country | United Kingdom |
Start | 03/2019 |
End | 01/2023 |
Description | UK Biobank - Whole genome sequencing of 50,000 UKB participants |
Amount | £30,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2020 |
Description | UK Biobank- Expansion of the UKB imaging to a 4th centre and repeat imaging assessment of 10,000 participants |
Amount | £8,500,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 12/2022 |
Description | UK Biobank Scientific Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London |
Year(s) Of Engagement Activity | 2018 |
Description | UK Biobank participant imaging event |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UK Biobank for participants of the imaging work |
Year(s) Of Engagement Activity | 2021 |
Description | UKBiobank participant events - 2014 - 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2020 over 4,000 participants have taken part in events in Edinburgh (4), Manchester (4), Nottingham, Leeds, Cardiff (2), Newcastle (5), Glasgow (2), Bristol (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing) |
Year(s) Of Engagement Activity | 2014,2015,2016,2017,2018,2019 |
URL | http://www.ukbiobank.ac.uk |